Acceptability, barriers and facilitators of using dried blood spots-point-of-care testing for sickle cell disease in Africa: an implementation science protocol for a multinational qualitative study

Autor: Andre Pascal Kengne, Leon Tshilolo, Grace Ndeezi, Nicola Mulder, Moses Joloba, Victoria Nembaware, Nchangwi Syntia Munung, Vivian Paintsil, Emmanuel Peprah, Fred Stephen Sarfo, Deogratias Munube, Collen Masimirembwa, Ambroise Wonkam, Daniel Ansong, Kwaku Ohene-Frempong, Ezekiel Mupere, Sarah Kiguli, Julie Makani, Josephine Mgaya, Siana Nkya, Fred Semitala, Raphael Zozimus Sangeda, Emmanuel Balandya, Anazoeze Madu, Catherine Chunda-Liyoka, Yeya Dit Sadio Sarro, Daudi Jjingo, Obiageli Eunice Nnodu, Lulu Chirande, Boubacari Ali Touré, Aldiouma Guindo, Patience Kuona, Kevin Esoh, Mario Jonas, Maxwell Nwegbu, Upendo Masamu, Jack Morrice, Patrick Ohiani Moru, Valentina Ngo Bitoungui, Hans Ackerman, Alex Osei Akoto, Emmanuela Ambrose, Evans Amuzu, Samuel Asala, Biobele Brown, Mmbando Bruno, Daima Bukini, Pamela Gorejena, Abdul Aziz Hassan, Justin Hokororo, Jade Hotchkiss, Abdoul Malik Idris, Hezekiah Isa, Agnes Jonathan, Gwendoline Q. Kandawasvika, Daniel Kandonga, Ibrahima Keita, Sekou Kene, Frank Makundi, Janeth Manongi, Hamakwa Mantina, Jason Maro, Irene Kida Minja, Khuthala Mnika, Takudzwa Mtisi, Wilson Mupfururirwa, Ritah Mutagonda, Ruth Namazzi, Solomon Ofori-Aquah, Emmanuel Okocha, Fumni Olopade, Jesca Ondego, Chandré Oosterwyk-Liu, Nash Oyekanmi, Stella Paul, Cynthia Phiri, Paschal Ruggajo, Parker Ruhl, Ian Machingura Ruredzo, Pauline Sambo, Sawabati Shabani, Florence Urio, Robert Opoka

Publikováno v: BMJ Open, Vol 14, Iss 11 (2024)

Background Sickle cell disease (SCD) is a prevalent inherited blood disorder. Globally, approximately 515 000 babies are born with SCD annually, with 75% of these births occurring in Africa. Integrating newborn screening (NBS) for SCD into primary he

Externí odkaz: https://doaj.org/article/071fae27709947318206425d2fa31a68

A protocol to clinically evaluate liquid biopsies as a tool to speed up diagnosis of children and young adults with aggressive infection-related lymphoma in East Africa '(AI-REAL)'

Autor: Ismail D. Legason, Martin D. Ogwang, Clara Chamba, Elifuraha Mkwizu, Claire El Mouden, Hadija Mwinula, Lulu Chirande, Anna Schuh, Faraja Chiwanga

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)

Abstract Background The capacity for invasive tissue biopsies followed by histopathology diagnosis in sub-Saharan Africa is severely limited. Consequently, many cancer patients are diagnosed late and outcomes are poor. Here, we propose to evaluate ci

Externí odkaz: https://doaj.org/article/62eb79e74cdc4ae7be804654b4b091e2

Development of multi-level standards of care recommendations for sickle cell disease: Experience from SickleInAfrica

Autor: Vivian Paintsil, Mwashungi Ally, Hezekiah Isa, Kofi A. Anie, Josephine Mgaya, Malula Nkanyemka, Victoria Nembaware, Yaa Gyamfua Oppong-Mensah, Flora Ndobho, Lulu Chirande, Abel Makubi, Obiageli Nnodu, Ambroise Wonkam, Julie Makani, Kwaku Ohene-Frempong

Publikováno v: Frontiers in Genetics, Vol 13 (2023)

Introduction: Sickle Cell Disease (SCD) causes significant morbidity and mortality particularly in sub-Saharan Africa (SSA) where it contributes to early childhood deaths. There is need to standardize treatment guidelines to help improve overall SCD

Externí odkaz: https://doaj.org/article/eef189073a754243aefe378963934b3e

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine [version 1; peer review: 2 approved]

Autor: Irene Kida, Paschal Rugajo, Hamu Mlyuka, Nathanael Sirili, Julie Makani, Agnes Jonathan, Lulu Chirande, Hilda Tutuba, Manase Kilonzi, Emmanuel Balandya

Publikováno v: F1000Research, Vol 11 (2022)

Hydroxyurea (HU) alone has the potential to prevent one out of every three deaths due to sickle cell disease (SCD) and almost all forms of disabilities caused by SCD. However, in Tanzania, only one out of every six registered SCD patients in the SPAR

Externí odkaz: https://doaj.org/article/b6966ffab64248eb907ac58ff78097cc

Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators

Autor: Hamu J. Mlyuka, Manase Kilonzi, Ritah F. Mutagonda, Lulu Chirande, Wigilya P. Mikomangwa, David T. Myemba, Godfrey Sambayi, Dorkasi L. Mwakawanga, Joyce Ndunguru, Agnes Jonathan, Julie Makani, Paschal Ruggajo, Irene K. Minja, Emmanuel Balandya, Appolinary A. R. Kamuhabwa

Publikováno v: Healthcare; Volume 10; Issue 11; Pages: 2223

Despite three decades of proven safety and effectiveness of hydroxyurea in modifying sickle cell disease (SCD), its accessibility is limited in Sub-Saharan Africa, which shares 75% of the world's SCD burden. Therefore, it is time to explore the barri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b1195f17086253d73bb1f00c481b9cf